Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta

Abstract

Interferon-beta (IFNβ) is a biological therapy which is immunogenic, inducing anti-IFN-β neutralizing antibodies (Nabs) in some subjects. The frequency of Nabs varies depending on IFN-β product and the Nab assay used.

Objective Assess frequency of Nabs using novel Luciferase assay, evaluate association with relapses, frequency of side effects and to compare results with published data.

Methods Serum samples at 12 and 24 months and a follow up sample were tested for binding and Nabs. Titre >20 NU was considered positive. Charts were reviewed retrospectively for clinical data.

Results Out of 327 subjects included, 130 subjects (40%) were binding antibody positive, 89 (27%) were Nab +ve at anytime. Risk at 12 months for being Nab +ve: Avonex 8%, Betaferon 39%, Rebif 33%, P < 10^-5; at 24 months 8, 31 and 27% respectively, P = 0.002. Nab titres were highest in Rebif Nab +ve subjects — 50% >320 NU. Annualized relapse rate was 1.53 pre-treatment, after treatment relapse rate was higher in Nab +ve group 0.67 (95% CI 0.38—0.97) versus 0.5 (0.38—0.61) Nab —ve P = 0.04. Nab status at 12 and 24 months was significantly associated with risk of subsequent relapse, risk being greatest in those with highest titres. Side effects were also significantly associated with Nab —ve status. Multiple Sclerosis 2008; 14: 212—218. http://msj.sagepub.com

Keywords

Multiple Sclerosis interferon beta binding antibody neutralizing antibody Luciferase assay

References

The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43(4): 655—61.

Paty DW , Li DK Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43(4): 662—67.

PRISMS Study Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56(12): 1628—36.

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352(9139): 1498—1504.

The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999; 53(4): 679—86.

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47(4): 889—94.

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39(3): 285—94.

Perini P. , Facchinetti A. , Bulian P. , Massaro AR , Pascalis DD , Bertolotto A. et al. Interferon-beta (INFbeta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001; 12(1): 56—61.

Ross C. , Clemmesen KM , Svenson M. , Sorensen PS , Koch-Henriksen N. , Skovgaard GL et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000; 48(5): 706—12.

10.

Panitch H. , Goodin DS , Francis G. , Chang P. , Coyle PK , O'Connor P. et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002; 59(10): 1496—1506.

11.

Clanet M. , Radue EW , Kappos L. , Hartung HP , Hohlfeld R. , Sandberg-Wollheim M. et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59(10): 1507—17.

12.

Sorensen PS , Ross C. , Clemmesen KM , Bendtzen K. , Frederiksen JL , Jensen K. et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362(9391): 1184—91.

13.

European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multi-centre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352(9139): 1491—7.

14.

Sorensen PS , Koch-Henriksen N. , Ross C. , Clemmesen KM , Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65(1): 33—39.

15.

Giovannoni G. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies. Neurology 2003; 61(9 Suppl 5): S13—S17.

16.

Hartung HP , Munschauer FE, III. Assessment and management of neutralizing antibodies in patients with multiple sclerosis. J Neurol 2004; 251 (Suppl 2): 1140—1142.

17.

Rice G. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 2001; 58(8): 1297—98.

18.

Francis GS , Rice GP , Alsop JC Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65(1): 48—55.

19.

Kappos L. , Clanet M. , Sandberg-Wollheim M. , Radue EW , Hartung HP , Hohlfeld R. et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65(1): 40—7.

20.

Pachner AR An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 2003; 61(10): 1444—46.

21.

Brickelmaier M. , Hochman PS , Baciu R. , Chao B. , Cuervo JH , Whitty A. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta. J Immunol Methods 1999; 227(1—2): 121—35.

22.

Grossberg SE , Kawade Y. , Kohase M. , Yokoyama H. , Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 2001; 21(9): 729—42.

23.

Grossberg SE , Kawade Y. , Kohase M. , Klein JP The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001; 21(9): 743—55.

24.

Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol 1986; 119: 558—73.

25.

Richert ND , Zierak MC , Bash CN , Lewis BK , McFarland HF , Frank JA MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b. Mult Scler 2000; 6(2): 86—90.

26.

Giovannoni G. , Goodman A.

Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?

Neurology 2005; 65(1): 6—8.

27.

Sorensen PS , Deisenhammer F. , Duda P. , Hohlfeld R. , Myhr KM , Palace J. et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12(11): 817—27.